Following results from a phase III trial, the FDA granted accelerated approval to pembrolizumab (Keytruda), in combination with chemotherapy, for metastatic or locally recurrent unresectable triple-negative breast cancer (TNBC).
The PD-1-directed immune checkpoint inhibitor is indicated for TNBC patients with a PD-L1 combined positive score (CPS) ≥10, based on findings from KEYNOTE-355 presented at the American Society of Clinical Oncology virtual meeting.
